IncobotulinumtoxinA for upper- and lower-limb spasticity in Japanese patients

References

• Leathley MJ, Gregson JM, Moore AP, et al. Predicting spasticity after stroke in those surviving to 12 months. Clin Rehabil. 2004;18(4):438–443.
   PubMed Web of Science ®Google Scholar
• Sommerfeld DK, Eek EU, Svensson AK, et al. Spasticity after stroke: its occurrence and association with motor impairments and activity limitations. Stroke. 2004;35(1):134–139.
   PubMed Web of Science ®Google Scholar
• Watkins CL, Leathley MJ, Gregson JM, et al. Prevalence of spasticity post stroke. Clin Rehabil. 2002;16(5):515–522.
   PubMed Web of Science ®Google Scholar
• Wissel J, Manack A, Brainin M. Toward an epidemiology of poststroke spasticity. Neurology. 2013;80(3 Suppl 2):S13–S19.
   PubMed Web of Science ®Google Scholar
• Lundström E, Smits A, Terént A, et al. Time-course and determinants of spasticity during the first six months following first-ever stroke. J Rehabil Med. 2010;42(4):296–301.
   PubMed Web of Science ®Google Scholar
• Mayer NH, Esquenazi A, Childers MK. Common patterns of clinical motor dysfunction. Muscle Nerve. 1997;6(Suppl):S21–S35.
   PubMed Web of Science ®Google Scholar
• Petrea RE, Beiser AS, Seshadri S, et al. Gender differences in stroke incidence and poststroke disability in the Framingham heart study. Stroke. 2009;40(4):1032–1037.
   PubMed Web of Science ®Google Scholar
• Willcox DC, Willcox BJ, Yasura S, et al. Gender gap in healthspan and life expectancy in Okinawa: health behaviours. Asian J Gerontol Geriatr. 2012;7:49–58.
   Google Scholar
• Shimizu H, Kawarai T, Saji N, et al. Re-evaluation of clinical features and risk factors of acute ischemic stroke in Japanese longevity society. Kobe J Med Sci. 2010;55(6):E132–E139.
   PubMedGoogle Scholar
• Reeves MJ, Bushnell CD, Howard G, et al. Sex differences in stroke: epidemiology, clinical presentation, medical care, and outcomes. Lancet Neurol. 2008;7(10):915–926.
   PubMed Web of Science ®Google Scholar
• Kaji R. Asian neurology and stroke. Neurology. 2015;84(10):1051–1052.
   PubMed Web of Science ®Google Scholar
• Esquenazi A, Novak I, Sheean G, et al. International consensus statement for the use of botulinum toxin treatment in adults and children with neurological impairments – introduction. Eur J Neurol. 2010;17(Suppl 2):1–8.
   PubMed Web of Science ®Google Scholar
• Royal College of Physicians, British Society of Rehabilitation Medicine, Chartered Society of Physiotherapy, et al. Spasticity in adults: management using botulinum toxin. National guidelines. 2009 [cited 2019 May 17]. Available from: https://www.rcplondon.ac.uk/sites/default/files/documents/spasticity-in-adults-management-botulinum-toxin.pdf
   Google Scholar
• Simpson DM, Hallett M, Ashman EJ, et al. Practice guideline update summary: botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2016;86(19):1818–1826.
   PubMed Web of Science ®Google Scholar
• Wissel J, Ward AB, Erztgaard P, et al. European consensus table on the use of botulinum toxin type A in adult spasticity. J Rehabil Med. 2009;41(1):13–25.
   PubMed Web of Science ®Google Scholar
• Allergan Inc. Highlights of Prescribing Information – Botox®. 2017 [cited 2018 Oct 2]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/103000s5302lbl.pdf
   Google Scholar
• Allergan Ltd. Botox® 100 U Summary of Product Characteristics. 2017 [cited 2018 Oct 2]. Available from: http://www.medicines.org.uk/EMC/medicine/112/SPC/
   Google Scholar
• Kaji R, Osako Y, Suyama K, et al. Botulinum toxin type A in post-stroke upper limb spasticity. Curr Med Res Opin. 2010;26(8):1983–1992.
   PubMed Web of Science ®Google Scholar
• Kaji R, Osako Y, Suyama K, et al. Botulinum toxin type A in post-stroke lower limb spasticity: a multicenter, double-blind, placebo-controlled trial. J Neurol. 2010;257(8):1330–1337.
   PubMed Web of Science ®Google Scholar
• Elovic EP, Munin MC, Kaňovský P, et al. Randomized, placebo-controlled trial of incobotulinumtoxinA for upper-limb post-stroke spasticity. Muscle Nerve. 2016;53(3):415–421.
   PubMed Web of Science ®Google Scholar
• Kaňovský P, Slawek J, Denes Z, et al. Efficacy and safety of botulinum neurotoxin NT 201 in poststroke upper limb spasticity. Clin Neuropharmacol. 2009;32(5):259–265.
   PubMed Web of Science ®Google Scholar
• Kaňovský P, Slawek J, Denes Z, et al. Efficacy and safety of treatment with incobotulinum toxin A (botulinum neurotoxin type A free from complexing proteins; NT 201) in post-stroke upper limb spasticity. J Rehabil Med. 2011;43(6):486–492.
   PubMed Web of Science ®Google Scholar
• Wissel J, Bensmail D, Ferreira JJ, et al. Safety and efficacy of incobotulinumtoxinA doses up to 800 U in limb spasticity: the TOWER study. Neurology. 2017;88(14):1321–1328.
   PubMed Web of Science ®Google Scholar
• Benecke R, Jost WH, Kaňovský P, et al. A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology. 2005;64(11):1949–1951.
   PubMed Web of Science ®Google Scholar
• Roggenkämper P, Jost WH, Bihari K, et al. Efficacy and safety of a new botulinum toxin type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm. 2006;113(3):303–312.
   PubMed Web of Science ®Google Scholar
• Wabbels B, Reichel G, Fulford-Smith A, et al. Double-blind, randomised, parallel group pilot study comparing two botulinum toxin type A products for the treatment of blepharospasm. J Neural Transm. 2011;118(2):233–239.
   PubMed Web of Science ®Google Scholar
• Merz Pharmaceuticals LLC. Highlights of Prescribing Information – Xeomin®. 2019 [cited 2019 May 17]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125360s074lbl.pdf
   Google Scholar
• Merz Pharma UK Ltd. Xeomin® (50/100/200) Summary of Product Characteristics. 2017 [cited 2019 May 17]. Available from: http://www.medicines.org.uk/emc/medicine/24582
   Google Scholar
• Masakado Y, Hanschmann A, Dekundy A. IncobotulinumtoxinA is efficacious and well-tolerated in Japanese subjects with post-stroke upper limb spasticity: a prospective, double-blind, placebo-controlled, randomized, multi-center study. P3–387. Poster presented at 13th International Society of Physical and Rehabilitation Medicine (ISPRM) World Congress; 2019 Jun 9–13; Kobe, Japan.
   Google Scholar
• Japan Pharmaceutical Information Center. JAPIC Clinical Trials Information. 2008 [cited 2018 Jun 9]. Available from: http://www.clinicaltrials.jp/user/cteSearch_e.jsp
   Google Scholar
• KDIGO CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2013;3(Suppl):1–150.
   Google Scholar
• Bensmail D, Hanschmann A, Wissel J. Satisfaction with botulinum toxin treatment in post-stroke spasticity: results from two cross-sectional surveys (patients and physicians). J Med Econ. 2014;17(9):618–625.
   PubMedGoogle Scholar
• Trompetto C, Marinelli L, Mori L, et al. Do flexible inter-injection intervals improve the effects of botulinum toxin A treatment in reducing impairment and disability in patients with spasticity? Med Hypotheses. 2017;102:28–32.
   PubMed Web of Science ®Google Scholar
• Feigin VL, Forouzanfar MH, Krishnamurthi R, et al. Global and regional burden of stroke during 1990–2010: findings from the Global Burden of Disease Study 2010. Lancet. 2014;383(9913):245–254.
   PubMed Web of Science ®Google Scholar
• van Asch CJ, Luitse MJ, Rinkel GJ, et al. Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis. Lancet Neurol. 2010;9(2):167–176.
   PubMed Web of Science ®Google Scholar
• Ishikawa S, Kayaba K, Gotoh T, et al. Incidence of total stroke, stroke subtypes, and myocardial infarction in the Japanese population: the JMS Cohort Study. J Epidemiol. 2008;18(4):144–150.
   PubMed Web of Science ®Google Scholar
• Ariesen MJ, Claus SP, Rinkel GJ, et al. Risk factors for intracerebral hemorrhage in the general population: a systematic review. Stroke. 2003;34(8):2060–2065.
   PubMed Web of Science ®Google Scholar
• Dressler D, Rychlik R, Kreimendahl F, et al. Long-term efficacy and safety of incobotulinumtoxinA and conventional treatment of poststroke arm spasticity: a prospective, non-interventional, open-label, parallel-group study. BMJ Open. 2015;5(12):e009358.
   PubMed Web of Science ®Google Scholar